Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
Sofosbuvir is a drug, which has been found useful in HCV (Hepatis C Virus) therapy. It replaced the previously used interferon, the applied of which has shown many side effects or lack of response to treatment. The usage of sofosbuvir with ribavirin shortens the time of treatment and minimizes the n...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2018-09-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/26378 |
| _version_ | 1811338361028214784 |
|---|---|
| author | Katarzyna Lipa Magdalena Julia Jabłońska Patryk Kaczor Kamil Leis Krystian Kałużny Przemysław Gałązka |
| author_facet | Katarzyna Lipa Magdalena Julia Jabłońska Patryk Kaczor Kamil Leis Krystian Kałużny Przemysław Gałązka |
| author_sort | Katarzyna Lipa |
| collection | DOAJ |
| description | Sofosbuvir is a drug, which has been found useful in HCV (Hepatis C Virus) therapy. It replaced the previously used interferon, the applied of which has shown many side effects or lack of response to treatment. The usage of sofosbuvir with ribavirin shortens the time of treatment and minimizes the number of side effects. It is taken as a single dose of 400 mg for 12 or 24 weeks. The only place of activation of this prodrug is hepatocytes, where its active metabolite is formed (GS-461203). It should not be used together with P-glycoprotein inductors that can reduce the efficiency of its action and with amiodarone, because application of both of them together slows down the heart rate. Numerous tests have demonstrated the effectiveness of sofosbuvir in the treatment of patients who have relapsed disease after liver transplantation. A high percentage of sustained virologic response obtained in all phases of clinical trials has proven the efficacy of sofosbuvir in combination with ribavirin or another HCV drug in the therapy of hepatitis C infection. |
| first_indexed | 2024-04-13T18:09:43Z |
| format | Article |
| id | doaj.art-d47abe6ccd67425fa9a4b4c788feed0b |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-04-13T18:09:43Z |
| publishDate | 2018-09-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-d47abe6ccd67425fa9a4b4c788feed0b2022-12-22T02:35:57ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062018-09-0189Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantationKatarzyna Lipa0Magdalena Julia Jabłońska1Patryk Kaczor2Kamil Leis3Krystian Kałużny4Przemysław Gałązka5Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in ToruńLudwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in ToruńLudwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in ToruńLudwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in ToruńLudwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in ToruńAntoni Jurasz University Hospital No. 1 in Bydgoszcz, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in ToruńSofosbuvir is a drug, which has been found useful in HCV (Hepatis C Virus) therapy. It replaced the previously used interferon, the applied of which has shown many side effects or lack of response to treatment. The usage of sofosbuvir with ribavirin shortens the time of treatment and minimizes the number of side effects. It is taken as a single dose of 400 mg for 12 or 24 weeks. The only place of activation of this prodrug is hepatocytes, where its active metabolite is formed (GS-461203). It should not be used together with P-glycoprotein inductors that can reduce the efficiency of its action and with amiodarone, because application of both of them together slows down the heart rate. Numerous tests have demonstrated the effectiveness of sofosbuvir in the treatment of patients who have relapsed disease after liver transplantation. A high percentage of sustained virologic response obtained in all phases of clinical trials has proven the efficacy of sofosbuvir in combination with ribavirin or another HCV drug in the therapy of hepatitis C infection.https://apcz.umk.pl/JEHS/article/view/26378sofosbuvirHepatis C Virusliver transplant |
| spellingShingle | Katarzyna Lipa Magdalena Julia Jabłońska Patryk Kaczor Kamil Leis Krystian Kałużny Przemysław Gałązka Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation Journal of Education, Health and Sport sofosbuvir Hepatis C Virus liver transplant |
| title | Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation |
| title_full | Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation |
| title_fullStr | Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation |
| title_full_unstemmed | Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation |
| title_short | Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation |
| title_sort | sofosbuvir as a drug in recurrent hcv therapy occurring after liver transplantation |
| topic | sofosbuvir Hepatis C Virus liver transplant |
| url | https://apcz.umk.pl/JEHS/article/view/26378 |
| work_keys_str_mv | AT katarzynalipa sofosbuvirasadruginrecurrenthcvtherapyoccurringafterlivertransplantation AT magdalenajuliajabłonska sofosbuvirasadruginrecurrenthcvtherapyoccurringafterlivertransplantation AT patrykkaczor sofosbuvirasadruginrecurrenthcvtherapyoccurringafterlivertransplantation AT kamilleis sofosbuvirasadruginrecurrenthcvtherapyoccurringafterlivertransplantation AT krystiankałuzny sofosbuvirasadruginrecurrenthcvtherapyoccurringafterlivertransplantation AT przemysławgałazka sofosbuvirasadruginrecurrenthcvtherapyoccurringafterlivertransplantation |